Boundless Bio, Common Stock Today
| BOLD Stock | USD 2.56 0.21 8.94% |
Performance0 of 100
| Odds Of DistressLess than 12
|
Boundless Bio, is trading at 2.56 as of the 25th of November 2024, a 8.94 percent up since the beginning of the trading day. The stock's lowest day price was 2.41. Boundless Bio, has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Boundless Bio, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of March 2024 | Category Healthcare | Classification Health Care |
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. Audentes Therapeutics, Inc. The company has 22.25 M outstanding shares of which 210.7 K shares are currently shorted by private and institutional investors with about 10.24 trading days to cover. More on Boundless Bio, Common
Moving against Boundless Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Boundless Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Zachary Hornby | |||||||||||||||||||||||||||||||||||||||||||||
| Old Name | 21S BOLD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Boundless Bio, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Boundless Bio,'s financial leverage. It provides some insight into what part of Boundless Bio,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Boundless Bio, Common (BOLD) is traded on NASDAQ Exchange in USA. It is located in 9880 Campus Point Drive, San Diego, CA, United States, 92121 and employs 72 people. Boundless Bio, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 79.89 M. Boundless Bio, Common conducts business under Biotechnology sector and is part of Health Care industry. The entity has 22.25 M outstanding shares of which 210.7 K shares are currently shorted by private and institutional investors with about 10.24 trading days to cover.
Boundless Bio, Common currently holds about 351.46 M in cash with (46.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Boundless Bio, Probability Of Bankruptcy
Ownership AllocationBoundless Bio, holds a total of 22.25 Million outstanding shares. The majority of Boundless Bio, Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Boundless Bio, Common to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Boundless Bio,. Please pay attention to any change in the institutional holdings of Boundless Bio, Common as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Boundless Ownership Details
Boundless Bio, Historical Income Statement
Boundless Stock Against Markets
Boundless Bio, Corporate Management
| Christian Hassig | Chief Officer | Profile | |
| MS MBA | Chief Officer | Profile | |
| Jessica JD | Chief Secretary | Profile | |
| Jamilu Rubin | Chief Officer | Profile | |
| Meredith Wesley | Senior Culture | Profile | |
| David Hinkle | Senior Controller | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.